Joseph K. Belanoff
to revenue ago, field I you, Thank endocrinology meeting. enthusiasm in and weeks afternoon. the team palpable. few have meet about prospects Atabak our performance highlighted our thank A our this guidance for XXXX. strong you, us joining national with for commercial in everyone, Charlie, and hypercortisolism set the was had our opportunity The we
with help more many to We patients have opportunity Cushing's the Syndrome.
was of a more reaching tipping are We far with the hypercortisolism than previously field medical sorts increasingly point is that understanding assumed. prevalent
to patients and reinforce the will of landmark with study future screening accurate understanding in emerging of investigators conducted diabetologists. study ever diabetes. I syndrome. this hypercortisolism difficult unquestionably top Catalyst treat patients are with this -- in the country's Its and prevalence clinical CATALYST guiding a to diagnosis IV is the X believe largest trial will Cushing's Phase ongoing Our examine type the be
keynote announced American will final Those those June. showed The than rate with from believed enroll Association's far them. community positioned to CATALYST The prevalence and for be many hypercortisolism results the many this Annual enroll case patients than enrolled. in Corcept The can XXX the results in found. X-part Diabetes Meeting This undoubtedly are in presented is results continues of session we phase. portion the population. be stimulate phase a XX% of physicians patients first results the a hypercortisolism preliminary Today, diagnosed are medical study. treatment higher from the the be prevalence a of to to will screen prevalence study to the hypercortisolism more is help will in in identified at CATALYST currently well patients
with the diagnosed invested journey an For and of based and patient needs that have patient more than individual services in advocacy we a all are decade, hypercortisolism. education support understanding on and
team these will we and are know come. of in years to a number help the we Our what of is prepared patients to proud growing programs, be
has and side of significant great are efficacy comes sense syndrome without knowing with of to urgency As of compelling of the working Cushing's the of effects a from advance sense relacorilant. urgency Korlym. awareness diagnosis increases, many we that the This compound
binding and levels receptor, to our some off-target a progesterone most compounds, of receptor receptor, therefore, including proprietary serious cause of They activated Korlym's to the is high. the bind modulate are not effects which do corticoid when group of effects. by don't All cortisol relacorilant, cortisol
GRADIENT. III trials We are and treatment of for evaluating the X relacorilant in hypercortisolism Phase GRACE
as the We positive data. Phase expect syndrome relacorilant's serve Cushing's on build basis II efficacy and submission in to GRACE safety and NDA for our to
Endocrinology discontinuation. improvements causes XXXX. Phase well trial endometrial experienced bleeding. as did related Progesterone of Cushing's published related Phase side cause Relacorilant's Korlym not meaningful of in effects, did results hypertension or the cause are glucose as in II and Relacorilant in including July side control a signs also Relacorilant symptoms hypokalemia study. II and of were other Patients thickening vaginal not the hypokalemia. drug-induced syndrome in Frontiers effects leading progesterone
in relacorilant Cushing's whose outcomes Patients is adenoma hypercortisolism, health this effects Our by a III including often but is decline, with of etiology rapid hyperplasia. gradient syndrome syndrome adrenal of patients second a experience Phase poor, are adrenal death. or premature an their higher trial Cushing's studying less in caused significantly risk
on to do an syndrome treatment expect patients. Cushing's of expect study that the our not valuable we etiology While do about many NDA depend syndrome to of in Cushing's GRADIENT, the data information we affects from provide efficacy
study Phase that relevant It findings previously bears repeating that far prevalent as CATALYST IV reinforces findings from many than was The is the CATALYST of to relacorilant will our more studies be ongoing indicating from assumed. the phase emerges. hypercortisolism first smaller it entirely
urgency are and Cushing's on said, we track syndrome our in second the relacorilant I with submit are to As great quarter. NDA we working
of We different are also treatment studying relacorilant types cancer. for as a
legal women. in replicate is plus this Enrollment alone. advanced the study are either of III be enrolled ROSELLA study in our design will Phase There ovarian our cancer, nab-paclitaxel a cancer in or of ROSELLA's trial with The the enthusiasm tracks II close investigators simply ovarian II the XXX goal great participating is platinum-resistant closely X:X relacorilant with most year. shortly, treatment our study ROSELLA in oncology useful Our randomized Women positive by end of results. paclitaxel available Phase planned to program is to and a options. will trial. cancer study Phase few among the data enrollment receive
overall The is with key primary end endpoint point. survival secondary progression-free survival, a
Group the from in Gynecological States United II well are conducting European leading Oncology Europe. in the successful Group with trial GOG Gynecological and women. clinicians meaningful our We benefit many GOT this controlled the correlate collaboration Network produced In of study to trials in and Phase Oncology
day the day lines treatment, improvement statistically to response progressed before, the including resensitize exhibited and monotherapy. compared chemotherapy's previous While more group progression-free nab-paclitaxel nab-paclitaxel or have tumors the received a received in beneficial who previous significant relacorilant these effects. day received women's their taxanes, appear after of of they X of the disease duration intermittently, Those to survival to have and on relacorilant
versus arm. those XX% The of of chemotherapy cortisol's in by anti-apoptotic took the comparator effect blunting the the effect. X in dermitielacora who XX% relacorilant start group live nab-paclitaxel were alone. of patients intermittent longer study addition also likely only do the alive enhance years after Women relacorilant who than
the who took women those relacorilant compared plus alone. as nab-paclitaxel who important, receive experienced Just nab-paclitaxel to burden effect no side additional
XXXX The results Society an of with from the Journal Medical European in of editorial. the accompanying featured and ASCO study Meeting. Annual in were American this been June in in published XXXX for Oncology, meetings and Society XXXX Clinical the XXXX have podium Oncology, Clinical presentations Results ESMO Oncology
relacorilant care effect an plus survival burden become ovarian that relacorilant's potential benefit important with a in oncologists advance progression-free has and platinum-resistant medical standard that have increased of us potential gynecological without the and women constitute new would side to Leading told nab-paclitaxel overall cancer. improved
modulation in of patients tumor prostate to is experience stimulation, antagonist may useful A reason by growth disease. enzalutamide, is tumor cancer second why mechanism stimulate prove by which androgen with androgen blocking major eventually receptor an activity treated Cortisol widely switched with GRIP. pathway. a stimulation prescribed a resurgent important Deprived cortisol to their cortisol
will a adding cortisol deprivation androgen to is hypothesis close tumor Our escape therapy modulator that route. this
had are collaborators patients Chicago a cancer an prostatectomy. plus before Phase with the randomized enzalutamide relacorilant trial II prostate of in have Our of patients enrolling University at placebo-controlled these initial
Cortisol suppresses to treat the the the enhancing effectiveness system. system, blunt which tumors cortisol response. third the The immune seeks immune intended mechanism cancer immune by of body's modulation to stimulate therapies may
therapies. hypothesis such may enhance these of modulator cortisol that adding the inhibitors, checkpoint a effectiveness Our as is immunotherapies to
pembrolizumab are excess PD-X advanced whose adrenal We of the plus checkpoint in Phase inhibitor tumors trial conducting a cortisol. patients Ib produce relacorilant cancer with
form monotherapy rarely is in as cancer. effective this adrenal of treating Pembrolizumab
are modulates our of clinical they effects. studies clinical each compounds and not evaluated activity, being identical, cortisol in they distinct produce selectively While
Some the blood-brain others barrier, not. do cross
investment Other models disease. models tumors. potent of Some of perform more in metabolic solid
matched more tissue These have us be to appear wide of compound. specific, Others a variety diverse using disorders to best allow Some qualities study effects. the global
and One of has and motor in atrophy. models these neuroinflammation edible compounds, improving ALS great performance reducing muscular dazucorilant, promise of shown
limited a know, halt you is progression. with prognosis options very poor disease As ALS to devastating a and
of a this is in placebo-controlled Enrollment primary of is on The Phase II based functional trial trial scale. data of rating speed ALS. will the expectations. our shortly in enrollment year. dazucorilant patients by DAZALS DAZALS the with endpoint The close available randomized Our with end double-blind ALS
NASH, a afflicts States. our that United liver treatment demonstrated to compelling of program early disorder evidence in for turn Miricorilant Finally, millions the has a people I'll in NASH. serious as
in and XXX triglycerides key Ib and lipid a of fat found measures, LDL. study and fibrosis received reduction liver who of Phase the twice orally dose-finding XX XX% weeks miricorilant markers with liver serum enzymes, metabolic HOMA-IR, Our for patients a experienced milligrams in including improvement week
also effects. tolerated Importantly, miricorilant GI well was side very no apparent with
double-blind, randomized, The a building BACE now of key to study, with reduction placebo-controlled Forward and these our promising the biopsy-confirmed results in improvement patients primary NASH NASH. as resolution fat secondary enrolling IIb endpoints. in on liver endpoint fibrosis is trial MONARCH actively with study
optimistic extremely are we about the conclusion, Corcept. future In of
Our on Cushing's we a scientific, have been foundation built is medical Syndrome years. holding and a solid commercial by expertise XX strengthening that over and franchise supported foundation, for is that
are this complex disease. Our to underscore strong the reflect ability results hypercortisolism as regularly physicians support for and our manage more them commercial screening they
CATALYST Cushing's or We the population goes syndrome our hypercortisolism. from and missed diabetes whose is better to study to identify expect difficult whose frequently help caused treat physicians by treat patients too undiagnosed. findings A
in tremendous the and we a track on treatment for patients second with Cushing's Relacorilant NDA submit syndrome, promise to are has quarter. as our demonstrated
development our potential that of generating modulation current examples. programs cancer, range cancer, are to NASH has Beyond ALS syndrome, increasing prostate Cushing's a the Ovarian wide diseases. treat and are cortisol evidence
with and potentially of research clinical a portfolio broad cortisol attributes. very active modulators many proprietary have We different selective
We advance clinic. to in therapeutic will we the in the attributes most compounds continue and to these will potential promising invest understanding applications, the
from CATALYST Corcept. Over trial our our exciting ALS. in pivotal we studies in our DASL syndrome, time and ovarian course of this Cushing's the data This cancer for and in expect Rosella GRADIENT trial year, an GRACE, is
for set than efforts employees XXX to of working more the appreciate are ambitious hard and goals the we our achieve ourselves. who have I dedication
want who oncology take to relacorilant and joined ago. Oncology a Corcept to Division we ovarian few our commercialization President resistant responsible as of questions, take a plate is expansion our in Before of cancer Viera, for Roberto, the footprint. of introduce years Roberto I the moment
hear more an over course opportunity XXXX. have him to from You'll of the
questions. proceed to let's now Operator,
